Document is current
Any future updates will be listed below
-
Authors
Alam, Taseen
Das, Nikhil
Maatouk, Christopher
Zhao, Alison
Singh, Rishi P.
Talcott, Katherine E. https://orcid.org/0000-0003-0458-4181
-
Funding
Funding for this research was provided by:
Research to Prevent Blindness (P30EY025585(BA-A), P30EY025585(BA-A))
- License Information
-
More Information
Article History
Received: 3 October 2024
Revised: 26 May 2025
Accepted: 22 August 2025
First Online: 12 September 2025
Competing interests
: KET reports personal fees from Alimera, Abbvie, Apellis, Astellas, Eyepoint, Genentech, Outlook, Regeneron, and Zeiss, and research fees from Regeneron and Zeiss.RPS reports personal fees from Apellis, Iveric, Eyepoint, Regnenxbio, Genentech, Bausch and Lomb, Zeiss, and sponsored research from Janssen. All other authors report no disclosures.
